Pancreatic Adenocarcinoma Articles & Analysis
10 news found
xCures, Inc. is proud to announce their partnership with RenovoRx, a clinical-stage biopharmaceutical company that focuses on fighting cancer through localized treatment of difficult-to-treat tumors, such as pancreatic adenocarcinoma. Through this collaboration, xCures will help eligible pancreatic cancer patients access a Phase III clinical ...
ByxCures
xCures, Inc. is proud to partner with Vault Health, a decentralized research and workforce screening company, to facilitate the enrollment of pancreatic cancer patients in Faeth Therapeutics’ NEAAR-001 research study. ...
ByxCures
Congratulations to investigators at Hannover School of Medicine and Heidelberg University Hospital for receiving the 2022 SNMMI Image of the Year Award and JNM Editors’ Choice Award for Overall Best Article in 2021, respectively. Both use FAPI as the primary indicator and further underscore its potential impact as a novel radiopharmaceutical. Each year, SNMMI chooses an image that best ...
BySOFIE
QN-302 (previously known as SOP1812) is the Company’s genomic quadruplex (G4)-selective transcription inhibitor platform being developed as a potential treatment for pancreatic ductal adenocarcinoma (PDAC), in addition to other tumors of high unmet clinical need. ...
Qualigen is developing this platform’s lead compound, now called QN-302, as a potential treatment for pancreatic ductal adenocarcinoma (PDAC), which represents the vast majority of pancreatic cancers. “Professor Neidle’s extensive knowledge in the development of QN-302 to date, as well as in the pancreatic ...
Qualigen intends to develop the lead compound, now called QN-302, as a treatment for pancreatic ductal adenocarcinoma (PDAC), which represents the vast majority of pancreatic cancers. ...
Rarecells Inc., a leading Liquid Biopsy company is pleased to announce the development of an innovative and accurate targeted digital single-cell Next-Generation Sequencing (scNGS) for single-nucleotide variant (SNV) method to detect mutant genes of pancreatic ductal adenocarcinoma (PDAC) circulating tumor cells (CTC) enriched by the ISET® technology. ...
The FiH clinical investigation will be conducted in a limited number of volunteers with pancreatic adenocarcinoma to evaluate the VectRx™ System design by gathering initial clinical safety and performance data useful in making any modifications to the final design. ...
In April 2017, NTO announced that the FDA had designated its VectRx™ thermal oncology treatment platform a 'Breakthrough Therapy' for Pancreatic Cancer, expediting patient access to this novel adjuvant therapy [1]. ...
The financing provides the resources to conduct human testing of NTO's VectRx™ thermal oncology treatment platform, designated by FDA as a 'Breakthrough Therapy' for Pancreatic Cancer, expediting patient access to this novel adjuvant therapy[1]. ...